News Releases

December 2019

December 20, 2019 12/20/2019 Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

December 13, 2019 12/13/2019 Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool

December 9, 2019 12/9/2019 Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

November 2019

November 6, 2019 11/6/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

October 2019

October 28, 2019 10/28/2019 First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes

October 10, 2019 10/10/2019 Working Mother Names Takeda as One of the 2019 100 Best Companies

September 2019

September 25, 2019 9/25/2019 First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

September 24, 2019 9/24/2019 Takeda Announces NATPARA® Special Use Program in the US